RT Journal Article
SR Electronic
T1 Determination of the LD<sub>50</sub> of Acridine Orange <em>via</em> Intravenous Administration in Mice in Preparation for Clinical Application to Cancer Therapy
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 523
OP 527
VO 28
IS 4
A1 TOMOKI NAKAMURA
A1 KATSUYUKI KUSUZAKI
A1 TAKAO MATSUBARA
A1 AKIHIKO MATSUMINE
A1 KUNIHIRO ASANUMA
A1 HARUHIKO SATONAKA
A1 ATSUMASA UCHIDA
A1 AKIHIRO SUDO
YR 2014
UL http://iv.iiarjournals.org/content/28/4/523.abstract
AB Aim: We undertook studies to determine the lethal dose 50 (LD50) of acridine orange (AO) using mice in order to confirm the safety of intravenous administration of AO. Materials and Methods: We used 40 mice and AO was administered once intravenously. General behavior and mortality were continuously observed for 14 days. At the end of the experiment, all animals were sacrificed for subsequent studies. Results: The LD50 for AO in male and female mice was determined to be 32 mg/kg and 36 mg/kg, respectively. Histopathological abnormalities were observed in only one mouse which died three days after the administration of AO. The other nine mice which died immediately after the administration of AO had no pathological findings in major organs. Conclusion: The clinical use of AO can be kept at 1.0 mg/kg or below and, therefore, intravenous administration of AO might be safe for use as cancer therapy.